During the corresponding time, Orasure Technologies Inc saw a revenue deteriorated by -1.93 % year on year, sequentially revenue grew by 10.2 %. While revenue at the Orasure Technologies Inc's corporate clients
Orasure Technologies Inc's Comment on Sales, Marketing and Customers
The company serves customers in the academic and research markets, disease risk management, diagnostics, pharmaceutical, biotech, and companion animal segments. It has developed collection devices for the microbiome market and a urine collection device primarily used in liquid biopsy and sexually transmitted disease markets. The company submitted a 510(k) to the FDA for its Colli-Pee® at-home urine collection device for sexually transmitted infections. Its principal product, the OraQuick® Rapid HIV Test, is sold under the OraQuick ADVANCE® name in North America, Europe, and other countries, and under the OraQuick® name in developing countries. The test detects HIV-1 and HIV-2 antibodies and is available for use in CLIA-certified laboratories and other sites with a CLIA waiver, including outreach clinics, community-based organizations, and physicians’ offices. The OraQuick ADVANCE® test is CE marked for sale in Europe and other countries accepting the CE mark and is registered for sale in other countries with distributors in place.
On December 2, 2024, OraSure Technologies, Inc. (NASDAQ: OSUR), a pioneering entity in point-of-care and home diagnostic tests, announced a significant advancement in infectious disease detection through its recent award from the Rapid Response Partnership Vehicle (RRPV). This pivotal funding, provided by the Biomedical Advanced Research and Development Authority (BARDA) a crucial component of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS) will propel the development of a rapid antigen test for Marburg Virus Disease (MVD), a severe and often fatal illness linked to viral hemorrhagic fever. The Threat of Marburg Virus DiseaseMarb...
Orasure Technologies Inc’s Comment on Sales, Marketing and Customers
The company serves customers in the academic and research markets, disease risk management, diagnostics, pharmaceutical, biotech, and companion animal segments. It has developed collection devices for the microbiome market and a urine collection device primarily used in liquid biopsy and sexually transmitted disease markets. The company submitted a 510(k) to the FDA for its Colli-Pee® at-home urine collection device for sexually transmitted infections. Its principal product, the OraQuick® Rapid HIV Test, is sold under the OraQuick ADVANCE® name in North America, Europe, and other countries, and under the OraQuick® name in developing countries. The test detects HIV-1 and HIV-2 antibodies and is available for use in CLIA-certified laboratories and other sites with a CLIA waiver, including outreach clinics, community-based organizations, and physicians’ offices. The OraQuick ADVANCE® test is CE marked for sale in Europe and other countries accepting the CE mark and is registered for sale in other countries with distributors in place.
Sources:
Orasure Technologies Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Orasure Technologies Inc’s corporate clients.
For your research, we’ve provided 9 tables on Orasure Technologies Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
183.1 %